Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
Portfolio Pulse from
Acurx Pharmaceuticals has published nonclinical in vivo data showing that its lead antibiotic candidate, ibezapolstat, has a more selective impact on the gut microbiome compared to other anti-CDI antibiotics. This positions ibezapolstat favorably as it advances to international Phase 3 clinical trials.
March 03, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acurx Pharmaceuticals' ibezapolstat demonstrates a more selective impact on the gut microbiome compared to other anti-CDI antibiotics, supporting its advancement to Phase 3 trials.
The publication of data showing ibezapolstat's selective impact on the gut microbiome compared to other antibiotics is a positive development for Acurx Pharmaceuticals. This supports the advancement of ibezapolstat to Phase 3 trials, which could lead to future approval and commercialization, potentially boosting ACXP's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100